These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 11367256)

  • 21. [The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
    Duval X
    Presse Med; 2000 Feb; 29(5):253-6. PubMed ID: 10701407
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiretroviral pharmacology issues and management.
    Piscitelli SC
    BETA; 1999; 12(4):9-15. PubMed ID: 11367266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emivirine: an NRTI that functions as an NNRTI.
    Cheonis N
    BETA; 1999; 12(4):7-8. PubMed ID: 11367264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
    Anta L; Blanco JL; Llibre JM; García F; Pérez-Elías MJ; Aguilera A; Pérez-Romero P; Caballero E; Vidal C; Cañizares A; Gutiérrez F; Dalmau D; Iribarren JA; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2013 Sep; 68(9):1994-2002. PubMed ID: 23629015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crossing the waters to the post-HAART era (or Jeanette meets Amalia).
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1999 Dec; 5(12):12-23, 28-33, 37-43, 47-51. PubMed ID: 11367348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1, 2, 3-current ways to fight HIV.
    Vazquez E
    Posit Aware; 1998; 9(6):31-3. PubMed ID: 11366478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV resistance: the new enemy.
    Colvin R
    Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study].
    Molina JM; Córdoba J; Gil A; Gobernado M
    Rev Esp Quimioter; 2007 Sep; 20(3):346-53. PubMed ID: 18080033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dupont data supports earlier findings.
    Slovick J
    Posit Living; 1999 Nov; 8(10):45. PubMed ID: 11367331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiclass primary antiretroviral drug resistance in a patient presenting HIV-1/2 dual infection.
    Castro E; Recordon-Pinson P; Cavassini M; Fleury H
    Antivir Ther; 2012; 17(3):593-4. PubMed ID: 22301389
    [No Abstract]   [Full Text] [Related]  

  • 31. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparing for the future.
    Cox S
    Posit Aware; 1997; 8(2):10-1. PubMed ID: 11364448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newer antiretroviral agents and how to use them.
    Kim HH; Daar ES
    Curr HIV/AIDS Rep; 2009 May; 6(2):55-62. PubMed ID: 19358775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspects of successful drug discovery and development.
    Pauwels R
    Antiviral Res; 2006 Sep; 71(2-3):77-89. PubMed ID: 16828174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 36. IDSA update from the city of brotherly love.
    Ghandi R
    Hopkins HIV Rep; 2000 Jan; 12(1):1, 4, 11. PubMed ID: 11366315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure.
    Briones C; Soriano V; González-Lahoz J
    AIDS; 2000 Jul; 14(11):1659-60. PubMed ID: 10983655
    [No Abstract]   [Full Text] [Related]  

  • 38. Understanding the reverse transcriptase inhibitors in HIV.
    Edmonds-Ogbuokiri J
    Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Boone LR
    Curr Opin Investig Drugs; 2006 Feb; 7(2):128-35. PubMed ID: 16499282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New antiretroviral agents: looking beyond protease and reverse transcriptase.
    Miller MD; Hazuda DJ
    Curr Opin Microbiol; 2001 Oct; 4(5):535-9. PubMed ID: 11587929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.